KOL presentations on Creo Core Products at DDW

Creo Medical

30/04/2026 07:00

RNS Number : 4820C

Creo Medical Group PLC

30 April 2026

 

 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

KOL presentations on Creo Core Products at DDW

Data presentations at Digestive Disease Week further validate Creo Medical's endoscopic devices

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that it will be attending the Digestive Disease Week ("DDW") 2026 conference in Chicago, IL, taking place between 2-5 May 2026 (booth 4536).

 

The conference will feature a range of presentations from Key Opinion Leaders ("KOLs") showcasing minimally invasive endoscopy procedures, with certain KOLs presenting studies further validating Creo Medical's endoscopic devices. Presentations include:

 

Zacharias P. Tsiamoulos, Director of Endoscopic Microsurgery Department at Hygeia Hospital, will present data as part of the ASGE World Cup displaying that sequential intermuscular and full thickness dissection with bipolar/microwave-assisted endoscopic submucosal dissection ("ESD") resulted in R0 resection and no postoperative complications. This study is significant in further validating Creo Medical's CROMA Advanced Energy Platform, powered by Kamaptive, which combines advanced bipolar radiofrequency and microwave energy to deliver safe and precise controlled coagulation.

 

Theodoros Alexopoulos, East Kent Hospitals University NHS Foundation Trust, will present prospective data from over 600 Speedboat™ assisted ESD cases for colorectal cancer, challenging the established 1mm cancer-free vertical margin threshold.

 

Eduardo Albéniz, Gastroenterology Specialist at Complejo Hospitalario de Navarra, will also be presenting an early experience study of bipolar knife peroral endoscopic myotomy ("POEM") using Speedboat™ and the CROMA Advanced Energy Platform. The study showed 100% technical success across 75 patients and demonstrates the potential benefits of POEM procedures with Speedboat and reduced instrument exchanges.

 

For more information about the event, please see the DDW website here.

 

For further information please contact: 

 

Creo Medical Group plc
www.creomedical.com
Richard Craven, Company Secretary
Via Walbrook PR
Deutsche Numis (Nominated Adviser, Joint Broker and Financial Adviser)
Duncan Monteith / Sher Shah
+44 (0)20 7260 1000
Shore Capital (Joint Broker)
Daniel Bush / Lucy Bowden
+44 (0)20 7408 4090
Walbrook PR Ltd
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 /+44 (0)7407 804 654


 

 

 

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAFFFFISFIAFIR